THERAPY DOSSIER · th-70b12ae33d12

Bone marrow-derived macrophages primed in vitro with recombinant TSG6 or recombinant IL-4, transferred adoptively

Biologic · Adoptive transfer of ex vivo-primed bone-marrow-derived macrophages; no ChEMBL entity (cell therapy plus recombinant protein priming). No ClinicalTrials.gov record for TSG-6 or for adoptively transferred primed macrophages in this configuration (searched, not assumed).

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Adoptive transfer of ex vivo-primed bone-marrow-derived macrophages; no ChEMBL entity (cell therapy plus recombinant protein priming). No ClinicalTrials.gov record for TSG-6 or for adoptively transferred primed macrophages in this configuration (searched, not assumed).
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31363052 ↗2019Reported benefit

STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation.

MouseEndotoxin/LPSC57BL/6Male and femalen = n = 6 mice per time point for BALF ELISA and alveolar macro…Macrophages by non-invasive intratracheal instillation; LPS intraperitoneallyIn vitro priming with TSG6 400 ng/mL or IL-4 100 ng/mL for…Simultaneous, with animals receiving LPS intraperitoneally and primed macrophag…

Model: Lipopolysaccharide-induced acute lung injury: single intraperitoneal dose of LPS 10 mg/kg (Escherichia coli 0111:B4) for injury, permeability and BALF studies, and a lethal dose of 20 mg/kg intraperitoneally for mortality studies

Intratracheal transfer of TSG6- or IL-4-primed bone marrow-derived macrophages increased survival after lethal LPS, reduced lung vascular permeability, reduced BALF neutrophil accumulation and lowered proinflammatory cytokines compared with unstimulated macrophages. The benefit required Gas6, since…

Extraction: extract · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…